nodes	percent_of_prediction	percent_of_DWPC	metapath
Midazolam—CYP2E1—Dacarbazine—muscle cancer	0.147	0.185	CbGbCtD
Midazolam—CYP3A7—Vincristine—muscle cancer	0.0814	0.102	CbGbCtD
Midazolam—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.0814	0.102	CbGbCtD
Midazolam—CYP2E1—Etoposide—muscle cancer	0.072	0.0903	CbGbCtD
Midazolam—ABCB1—Dactinomycin—muscle cancer	0.0645	0.0809	CbGbCtD
Midazolam—CYP3A5—Vincristine—muscle cancer	0.061	0.0766	CbGbCtD
Midazolam—CYP3A5—Etoposide—muscle cancer	0.0559	0.0702	CbGbCtD
Midazolam—CYP2B6—Doxorubicin—muscle cancer	0.0484	0.0607	CbGbCtD
Midazolam—ABCB1—Vincristine—muscle cancer	0.0397	0.0498	CbGbCtD
Midazolam—ABCB1—Etoposide—muscle cancer	0.0364	0.0457	CbGbCtD
Midazolam—ABCB1—Doxorubicin—muscle cancer	0.0248	0.0311	CbGbCtD
Midazolam—ABCB1—Methotrexate—muscle cancer	0.024	0.0302	CbGbCtD
Midazolam—CYP3A4—Vincristine—muscle cancer	0.0238	0.0299	CbGbCtD
Midazolam—CYP3A4—Etoposide—muscle cancer	0.0218	0.0274	CbGbCtD
Midazolam—CYP3A4—Doxorubicin—muscle cancer	0.0149	0.0187	CbGbCtD
Midazolam—UGT1A4—renal system—muscle cancer	0.00367	0.0447	CbGeAlD
Midazolam—Skin necrosis—Etoposide—muscle cancer	0.00361	0.0299	CcSEcCtD
Midazolam—Obstructive airways disorder—Methotrexate—muscle cancer	0.00333	0.0276	CcSEcCtD
Midazolam—CYP4B1—cardiac atrium—muscle cancer	0.00324	0.0395	CbGeAlD
Midazolam—CYP4B1—tendon—muscle cancer	0.00283	0.0344	CbGeAlD
Midazolam—Induration—Etoposide—muscle cancer	0.00282	0.0234	CcSEcCtD
Midazolam—CYP4B1—vagina—muscle cancer	0.00262	0.0319	CbGeAlD
Midazolam—CYP4B1—head—muscle cancer	0.00242	0.0295	CbGeAlD
Midazolam—CYP4B1—testis—muscle cancer	0.00234	0.0285	CbGeAlD
Midazolam—GABRR2—tendon—muscle cancer	0.00227	0.0277	CbGeAlD
Midazolam—GABRR3—head—muscle cancer	0.00225	0.0274	CbGeAlD
Midazolam—GABRQ—head—muscle cancer	0.00225	0.0274	CbGeAlD
Midazolam—Nystagmus—Vincristine—muscle cancer	0.00218	0.0181	CcSEcCtD
Midazolam—Skin necrosis—Methotrexate—muscle cancer	0.00216	0.0179	CcSEcCtD
Midazolam—Warmth—Doxorubicin—muscle cancer	0.00206	0.017	CcSEcCtD
Midazolam—GABRG3—head—muscle cancer	0.00197	0.024	CbGeAlD
Midazolam—GABRR2—head—muscle cancer	0.00195	0.0237	CbGeAlD
Midazolam—GABRG3—testis—muscle cancer	0.0019	0.0232	CbGeAlD
Midazolam—GABRR1—head—muscle cancer	0.00188	0.0228	CbGeAlD
Midazolam—Skin necrosis—Doxorubicin—muscle cancer	0.00187	0.0155	CcSEcCtD
Midazolam—GABRR1—testis—muscle cancer	0.00181	0.0221	CbGeAlD
Midazolam—Laryngospasm—Etoposide—muscle cancer	0.00169	0.014	CcSEcCtD
Midazolam—GABRB1—vagina—muscle cancer	0.00165	0.0201	CbGeAlD
Midazolam—GABRD—head—muscle cancer	0.00163	0.0199	CbGeAlD
Midazolam—GABRA4—tendon—muscle cancer	0.0016	0.0195	CbGeAlD
Midazolam—Respiratory failure—Vincristine—muscle cancer	0.00158	0.0131	CcSEcCtD
Midazolam—GABRD—testis—muscle cancer	0.00158	0.0192	CbGeAlD
Midazolam—GABRG1—head—muscle cancer	0.00157	0.0191	CbGeAlD
Midazolam—GABRA6—head—muscle cancer	0.00156	0.019	CbGeAlD
Midazolam—GABRB1—head—muscle cancer	0.00152	0.0185	CbGeAlD
Midazolam—GABRA5—head—muscle cancer	0.00151	0.0184	CbGeAlD
Midazolam—Apnoea—Etoposide—muscle cancer	0.00149	0.0123	CcSEcCtD
Midazolam—SLC22A1—renal system—muscle cancer	0.00148	0.018	CbGeAlD
Midazolam—GABRP—vagina—muscle cancer	0.00148	0.018	CbGeAlD
Midazolam—Phlebitis—Dactinomycin—muscle cancer	0.00147	0.0122	CcSEcCtD
Midazolam—GABRA5—testis—muscle cancer	0.00146	0.0178	CbGeAlD
Midazolam—GABRA3—head—muscle cancer	0.00141	0.0172	CbGeAlD
Midazolam—GABRE—cardiac atrium—muscle cancer	0.00139	0.017	CbGeAlD
Midazolam—GABRA4—head—muscle cancer	0.00137	0.0167	CbGeAlD
Midazolam—GABRP—head—muscle cancer	0.00136	0.0166	CbGeAlD
Midazolam—GABRA3—testis—muscle cancer	0.00136	0.0166	CbGeAlD
Midazolam—Fracture—Methotrexate—muscle cancer	0.0013	0.0108	CcSEcCtD
Midazolam—Multiple fractures—Methotrexate—muscle cancer	0.0013	0.0108	CcSEcCtD
Midazolam—Lethargy—Dactinomycin—muscle cancer	0.00129	0.0107	CcSEcCtD
Midazolam—GABRE—tendon—muscle cancer	0.00121	0.0148	CbGeAlD
Midazolam—Skin exfoliation—Etoposide—muscle cancer	0.0012	0.00997	CcSEcCtD
Midazolam—Hypoxia—Methotrexate—muscle cancer	0.00119	0.00985	CcSEcCtD
Midazolam—Local reaction—Doxorubicin—muscle cancer	0.00118	0.00979	CcSEcCtD
Midazolam—GABRB2—head—muscle cancer	0.00115	0.014	CbGeAlD
Midazolam—GABRG2—head—muscle cancer	0.00115	0.014	CbGeAlD
Midazolam—GABRA2—vagina—muscle cancer	0.00114	0.0138	CbGeAlD
Midazolam—GABRE—vagina—muscle cancer	0.00113	0.0137	CbGeAlD
Midazolam—GABRB2—testis—muscle cancer	0.00111	0.0135	CbGeAlD
Midazolam—Cardiac arrest—Vincristine—muscle cancer	0.00107	0.0089	CcSEcCtD
Midazolam—SLC22A1—vagina—muscle cancer	0.00107	0.0131	CbGeAlD
Midazolam—Ataxia—Vincristine—muscle cancer	0.00106	0.0088	CcSEcCtD
Midazolam—Phlebitis—Etoposide—muscle cancer	0.00106	0.0088	CcSEcCtD
Midazolam—GABRA2—head—muscle cancer	0.00105	0.0128	CbGeAlD
Midazolam—GABRE—head—muscle cancer	0.00104	0.0127	CbGeAlD
Midazolam—Swelling—Etoposide—muscle cancer	0.00104	0.0086	CcSEcCtD
Midazolam—GABRA1—head—muscle cancer	0.00101	0.0124	CbGeAlD
Midazolam—GABRE—testis—muscle cancer	0.00101	0.0122	CbGeAlD
Midazolam—Muscular weakness—Vincristine—muscle cancer	0.000996	0.00826	CcSEcCtD
Midazolam—SLC22A1—head—muscle cancer	0.000991	0.0121	CbGeAlD
Midazolam—Redness—Doxorubicin—muscle cancer	0.000969	0.00803	CcSEcCtD
Midazolam—Hyperventilation—Doxorubicin—muscle cancer	0.00095	0.00787	CcSEcCtD
Midazolam—Anaphylactoid reaction—Etoposide—muscle cancer	0.000946	0.00783	CcSEcCtD
Midazolam—Cardiac failure—Etoposide—muscle cancer	0.000938	0.00777	CcSEcCtD
Midazolam—Thrombosis—Doxorubicin—muscle cancer	0.000924	0.00765	CcSEcCtD
Midazolam—Nystagmus—Doxorubicin—muscle cancer	0.000916	0.00759	CcSEcCtD
Midazolam—CYP3A5—renal system—muscle cancer	0.0009	0.011	CbGeAlD
Midazolam—CYP2B6—renal system—muscle cancer	0.000894	0.0109	CbGeAlD
Midazolam—Apnoea—Methotrexate—muscle cancer	0.000891	0.00738	CcSEcCtD
Midazolam—GABRB3—head—muscle cancer	0.000882	0.0107	CbGeAlD
Midazolam—Cardiac arrest—Etoposide—muscle cancer	0.00087	0.00721	CcSEcCtD
Midazolam—Depression—Vincristine—muscle cancer	0.000868	0.00719	CcSEcCtD
Midazolam—Neuropathy peripheral—Vincristine—muscle cancer	0.000853	0.00707	CcSEcCtD
Midazolam—GABRB3—testis—muscle cancer	0.000852	0.0104	CbGeAlD
Midazolam—Musculoskeletal stiffness—Methotrexate—muscle cancer	0.000842	0.00697	CcSEcCtD
Midazolam—CYP2E1—renal system—muscle cancer	0.000839	0.0102	CbGeAlD
Midazolam—Feeling hot—Doxorubicin—muscle cancer	0.000833	0.0069	CcSEcCtD
Midazolam—Injection site pain—Doxorubicin—muscle cancer	0.000801	0.00664	CcSEcCtD
Midazolam—Dysarthria—Methotrexate—muscle cancer	0.000798	0.00662	CcSEcCtD
Midazolam—Dysphonia—Doxorubicin—muscle cancer	0.000795	0.00659	CcSEcCtD
Midazolam—Chills—Dactinomycin—muscle cancer	0.000785	0.0065	CcSEcCtD
Midazolam—Bronchospasm—Etoposide—muscle cancer	0.000778	0.00645	CcSEcCtD
Midazolam—Hallucination—Vincristine—muscle cancer	0.000778	0.00644	CcSEcCtD
Midazolam—Respiratory failure—Methotrexate—muscle cancer	0.000769	0.00637	CcSEcCtD
Midazolam—Connective tissue disorder—Vincristine—muscle cancer	0.000768	0.00636	CcSEcCtD
Midazolam—Erythema—Dactinomycin—muscle cancer	0.000762	0.00631	CcSEcCtD
Midazolam—Delirium—Doxorubicin—muscle cancer	0.00076	0.0063	CcSEcCtD
Midazolam—Depressed level of consciousness—Methotrexate—muscle cancer	0.000729	0.00604	CcSEcCtD
Midazolam—Cardiac disorder—Vincristine—muscle cancer	0.000725	0.00601	CcSEcCtD
Midazolam—Ventricular extrasystoles—Doxorubicin—muscle cancer	0.000724	0.006	CcSEcCtD
Midazolam—Skin exfoliation—Methotrexate—muscle cancer	0.000721	0.00597	CcSEcCtD
Midazolam—Mediastinal disorder—Vincristine—muscle cancer	0.000704	0.00584	CcSEcCtD
Midazolam—Dyskinesia—Doxorubicin—muscle cancer	0.000696	0.00577	CcSEcCtD
Midazolam—Dysarthria—Doxorubicin—muscle cancer	0.000691	0.00573	CcSEcCtD
Midazolam—Neuropathy peripheral—Etoposide—muscle cancer	0.000691	0.00573	CcSEcCtD
Midazolam—Mental disorder—Vincristine—muscle cancer	0.000685	0.00567	CcSEcCtD
Midazolam—CYP3A4—renal system—muscle cancer	0.000675	0.00822	CbGeAlD
Midazolam—CYP2E1—tendon—muscle cancer	0.000655	0.00797	CbGeAlD
Midazolam—Hiccups—Doxorubicin—muscle cancer	0.000654	0.00542	CcSEcCtD
Midazolam—Ventricular tachycardia—Doxorubicin—muscle cancer	0.000654	0.00542	CcSEcCtD
Midazolam—CYP3A5—vagina—muscle cancer	0.000652	0.00793	CbGeAlD
Midazolam—CYP2B6—vagina—muscle cancer	0.000648	0.00788	CbGeAlD
Midazolam—Salivary hypersecretion—Doxorubicin—muscle cancer	0.000635	0.00526	CcSEcCtD
Midazolam—Thrombophlebitis—Methotrexate—muscle cancer	0.000633	0.00525	CcSEcCtD
Midazolam—ABCB1—embryo—muscle cancer	0.000631	0.00769	CbGeAlD
Midazolam—Agitation—Vincristine—muscle cancer	0.000625	0.00518	CcSEcCtD
Midazolam—Skin exfoliation—Doxorubicin—muscle cancer	0.000624	0.00517	CcSEcCtD
Midazolam—Vertigo—Vincristine—muscle cancer	0.000611	0.00506	CcSEcCtD
Midazolam—CYP2B6—head—muscle cancer	0.000598	0.00728	CbGeAlD
Midazolam—Eye disorder—Etoposide—muscle cancer	0.000592	0.0049	CcSEcCtD
Midazolam—Cardiac disorder—Etoposide—muscle cancer	0.000588	0.00487	CcSEcCtD
Midazolam—Visual disturbance—Methotrexate—muscle cancer	0.000578	0.00479	CcSEcCtD
Midazolam—CYP2B6—testis—muscle cancer	0.000578	0.00704	CbGeAlD
Midazolam—Immune system disorder—Etoposide—muscle cancer	0.000572	0.00474	CcSEcCtD
Midazolam—Mediastinal disorder—Etoposide—muscle cancer	0.000571	0.00473	CcSEcCtD
Midazolam—Chills—Etoposide—muscle cancer	0.000568	0.00471	CcSEcCtD
Midazolam—Anaphylactoid reaction—Methotrexate—muscle cancer	0.000566	0.00469	CcSEcCtD
Midazolam—CYP2E1—head—muscle cancer	0.000561	0.00683	CbGeAlD
Midazolam—Lethargy—Methotrexate—muscle cancer	0.000559	0.00464	CcSEcCtD
Midazolam—Anaphylactic shock—Vincristine—muscle cancer	0.000555	0.0046	CcSEcCtD
Midazolam—Phlebitis—Doxorubicin—muscle cancer	0.000551	0.00457	CcSEcCtD
Midazolam—Thrombophlebitis—Doxorubicin—muscle cancer	0.000548	0.00454	CcSEcCtD
Midazolam—Osteoarthritis—Methotrexate—muscle cancer	0.000548	0.00454	CcSEcCtD
Midazolam—Nervous system disorder—Vincristine—muscle cancer	0.000545	0.00451	CcSEcCtD
Midazolam—CYP2E1—testis—muscle cancer	0.000542	0.0066	CbGeAlD
Midazolam—Fatigue—Dactinomycin—muscle cancer	0.000536	0.00444	CcSEcCtD
Midazolam—Pain—Dactinomycin—muscle cancer	0.000531	0.0044	CcSEcCtD
Midazolam—Irritability—Methotrexate—muscle cancer	0.000523	0.00434	CcSEcCtD
Midazolam—Mood swings—Methotrexate—muscle cancer	0.000519	0.0043	CcSEcCtD
Midazolam—Hypotension—Vincristine—muscle cancer	0.000519	0.0043	CcSEcCtD
Midazolam—Ataxia—Methotrexate—muscle cancer	0.000515	0.00427	CcSEcCtD
Midazolam—Feeling abnormal—Dactinomycin—muscle cancer	0.000512	0.00424	CcSEcCtD
Midazolam—Paraesthesia—Vincristine—muscle cancer	0.000499	0.00413	CcSEcCtD
Midazolam—Vertigo—Etoposide—muscle cancer	0.000495	0.0041	CcSEcCtD
Midazolam—Anaphylactoid reaction—Doxorubicin—muscle cancer	0.00049	0.00406	CcSEcCtD
Midazolam—Cardiac failure—Doxorubicin—muscle cancer	0.000486	0.00403	CcSEcCtD
Midazolam—Lethargy—Doxorubicin—muscle cancer	0.000484	0.00401	CcSEcCtD
Midazolam—Cough—Etoposide—muscle cancer	0.000481	0.00398	CcSEcCtD
Midazolam—Gastrointestinal disorder—Vincristine—muscle cancer	0.000479	0.00397	CcSEcCtD
Midazolam—Fatigue—Vincristine—muscle cancer	0.000479	0.00397	CcSEcCtD
Midazolam—ABCB1—renal system—muscle cancer	0.000478	0.00582	CbGeAlD
Midazolam—Constipation—Vincristine—muscle cancer	0.000475	0.00393	CcSEcCtD
Midazolam—Pain—Vincristine—muscle cancer	0.000475	0.00393	CcSEcCtD
Midazolam—Diplopia—Doxorubicin—muscle cancer	0.000475	0.00393	CcSEcCtD
Midazolam—Osteoarthritis—Doxorubicin—muscle cancer	0.000475	0.00393	CcSEcCtD
Midazolam—Affect lability—Doxorubicin—muscle cancer	0.000467	0.00387	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000466	0.00386	CcSEcCtD
Midazolam—Hypersensitivity—Dactinomycin—muscle cancer	0.000458	0.00379	CcSEcCtD
Midazolam—Confusional state—Etoposide—muscle cancer	0.000454	0.00376	CcSEcCtD
Midazolam—Cardiac arrest—Doxorubicin—muscle cancer	0.000451	0.00374	CcSEcCtD
Midazolam—Anaphylactic shock—Etoposide—muscle cancer	0.00045	0.00373	CcSEcCtD
Midazolam—Mood swings—Doxorubicin—muscle cancer	0.00045	0.00373	CcSEcCtD
Midazolam—Ataxia—Doxorubicin—muscle cancer	0.000446	0.0037	CcSEcCtD
Midazolam—Asthenia—Dactinomycin—muscle cancer	0.000446	0.00369	CcSEcCtD
Midazolam—Tachycardia—Etoposide—muscle cancer	0.000439	0.00364	CcSEcCtD
Midazolam—Skin disorder—Etoposide—muscle cancer	0.000437	0.00362	CcSEcCtD
Midazolam—Nasopharyngitis—Doxorubicin—muscle cancer	0.000424	0.00352	CcSEcCtD
Midazolam—Drowsiness—Methotrexate—muscle cancer	0.000422	0.0035	CcSEcCtD
Midazolam—Depression—Methotrexate—muscle cancer	0.000421	0.00349	CcSEcCtD
Midazolam—Hypotension—Etoposide—muscle cancer	0.00042	0.00348	CcSEcCtD
Midazolam—Muscular weakness—Doxorubicin—muscle cancer	0.000419	0.00347	CcSEcCtD
Midazolam—Hypersensitivity—Vincristine—muscle cancer	0.000409	0.00339	CcSEcCtD
Midazolam—Paraesthesia—Etoposide—muscle cancer	0.000404	0.00335	CcSEcCtD
Midazolam—Dyspnoea—Etoposide—muscle cancer	0.000401	0.00332	CcSEcCtD
Midazolam—Somnolence—Etoposide—muscle cancer	0.0004	0.00331	CcSEcCtD
Midazolam—Asthenia—Vincristine—muscle cancer	0.000398	0.0033	CcSEcCtD
Midazolam—Vomiting—Dactinomycin—muscle cancer	0.000395	0.00327	CcSEcCtD
Midazolam—Rash—Dactinomycin—muscle cancer	0.000392	0.00325	CcSEcCtD
Midazolam—Gastrointestinal disorder—Etoposide—muscle cancer	0.000388	0.00322	CcSEcCtD
Midazolam—Fatigue—Etoposide—muscle cancer	0.000388	0.00321	CcSEcCtD
Midazolam—Pain—Etoposide—muscle cancer	0.000385	0.00319	CcSEcCtD
Midazolam—Constipation—Etoposide—muscle cancer	0.000385	0.00319	CcSEcCtD
Midazolam—Feeling abnormal—Etoposide—muscle cancer	0.000371	0.00307	CcSEcCtD
Midazolam—Nausea—Dactinomycin—muscle cancer	0.000369	0.00306	CcSEcCtD
Midazolam—Dizziness—Vincristine—muscle cancer	0.000367	0.00304	CcSEcCtD
Midazolam—Drowsiness—Doxorubicin—muscle cancer	0.000366	0.00303	CcSEcCtD
Midazolam—Visual impairment—Methotrexate—muscle cancer	0.000365	0.00303	CcSEcCtD
Midazolam—ABCB1—bone marrow—muscle cancer	0.000361	0.0044	CbGeAlD
Midazolam—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000359	0.00297	CcSEcCtD
Midazolam—Urticaria—Etoposide—muscle cancer	0.000357	0.00296	CcSEcCtD
Midazolam—Eye disorder—Methotrexate—muscle cancer	0.000354	0.00294	CcSEcCtD
Midazolam—Vomiting—Vincristine—muscle cancer	0.000353	0.00293	CcSEcCtD
Midazolam—Cardiac disorder—Methotrexate—muscle cancer	0.000352	0.00292	CcSEcCtD
Midazolam—Rash—Vincristine—muscle cancer	0.00035	0.0029	CcSEcCtD
Midazolam—Dermatitis—Vincristine—muscle cancer	0.00035	0.0029	CcSEcCtD
Midazolam—Headache—Vincristine—muscle cancer	0.000348	0.00288	CcSEcCtD
Midazolam—ABCB1—vagina—muscle cancer	0.000346	0.00421	CbGeAlD
Midazolam—Immune system disorder—Methotrexate—muscle cancer	0.000343	0.00284	CcSEcCtD
Midazolam—Mediastinal disorder—Methotrexate—muscle cancer	0.000342	0.00283	CcSEcCtD
Midazolam—Chills—Methotrexate—muscle cancer	0.00034	0.00282	CcSEcCtD
Midazolam—Bradycardia—Doxorubicin—muscle cancer	0.000334	0.00277	CcSEcCtD
Midazolam—Mental disorder—Methotrexate—muscle cancer	0.000332	0.00275	CcSEcCtD
Midazolam—Hypersensitivity—Etoposide—muscle cancer	0.000331	0.00275	CcSEcCtD
Midazolam—Erythema—Methotrexate—muscle cancer	0.00033	0.00274	CcSEcCtD
Midazolam—Nausea—Vincristine—muscle cancer	0.00033	0.00273	CcSEcCtD
Midazolam—Asthenia—Etoposide—muscle cancer	0.000323	0.00267	CcSEcCtD
Midazolam—Connective tissue disorder—Doxorubicin—muscle cancer	0.000323	0.00267	CcSEcCtD
Midazolam—ABCB1—head—muscle cancer	0.00032	0.00389	CbGeAlD
Midazolam—Pruritus—Etoposide—muscle cancer	0.000318	0.00264	CcSEcCtD
Midazolam—Visual impairment—Doxorubicin—muscle cancer	0.000316	0.00262	CcSEcCtD
Midazolam—Vision blurred—Methotrexate—muscle cancer	0.000311	0.00258	CcSEcCtD
Midazolam—ABCB1—testis—muscle cancer	0.000309	0.00376	CbGeAlD
Midazolam—Eye disorder—Doxorubicin—muscle cancer	0.000307	0.00254	CcSEcCtD
Midazolam—Cardiac disorder—Doxorubicin—muscle cancer	0.000305	0.00253	CcSEcCtD
Midazolam—Dizziness—Etoposide—muscle cancer	0.000297	0.00246	CcSEcCtD
Midazolam—Immune system disorder—Doxorubicin—muscle cancer	0.000297	0.00246	CcSEcCtD
Midazolam—Vertigo—Methotrexate—muscle cancer	0.000297	0.00246	CcSEcCtD
Midazolam—Mediastinal disorder—Doxorubicin—muscle cancer	0.000296	0.00245	CcSEcCtD
Midazolam—Chills—Doxorubicin—muscle cancer	0.000295	0.00244	CcSEcCtD
Midazolam—Cough—Methotrexate—muscle cancer	0.000288	0.00239	CcSEcCtD
Midazolam—Mental disorder—Doxorubicin—muscle cancer	0.000288	0.00238	CcSEcCtD
Midazolam—Vomiting—Etoposide—muscle cancer	0.000286	0.00237	CcSEcCtD
Midazolam—Erythema—Doxorubicin—muscle cancer	0.000286	0.00237	CcSEcCtD
Midazolam—Rash—Etoposide—muscle cancer	0.000284	0.00235	CcSEcCtD
Midazolam—Dermatitis—Etoposide—muscle cancer	0.000283	0.00235	CcSEcCtD
Midazolam—Headache—Etoposide—muscle cancer	0.000282	0.00233	CcSEcCtD
Midazolam—Tension—Doxorubicin—muscle cancer	0.000281	0.00232	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000279	0.00231	CcSEcCtD
Midazolam—Nervousness—Doxorubicin—muscle cancer	0.000278	0.0023	CcSEcCtD
Midazolam—Confusional state—Methotrexate—muscle cancer	0.000272	0.00225	CcSEcCtD
Midazolam—Anaphylactic shock—Methotrexate—muscle cancer	0.000269	0.00223	CcSEcCtD
Midazolam—Vision blurred—Doxorubicin—muscle cancer	0.000269	0.00223	CcSEcCtD
Midazolam—Nausea—Etoposide—muscle cancer	0.000267	0.00221	CcSEcCtD
Midazolam—Nervous system disorder—Methotrexate—muscle cancer	0.000264	0.00219	CcSEcCtD
Midazolam—Agitation—Doxorubicin—muscle cancer	0.000263	0.00218	CcSEcCtD
Midazolam—Skin disorder—Methotrexate—muscle cancer	0.000262	0.00217	CcSEcCtD
Midazolam—Vertigo—Doxorubicin—muscle cancer	0.000257	0.00213	CcSEcCtD
Midazolam—Syncope—Doxorubicin—muscle cancer	0.000256	0.00212	CcSEcCtD
Midazolam—Hypotension—Methotrexate—muscle cancer	0.000252	0.00209	CcSEcCtD
Midazolam—Cough—Doxorubicin—muscle cancer	0.000249	0.00207	CcSEcCtD
Midazolam—Anxiety—Doxorubicin—muscle cancer	0.000243	0.00201	CcSEcCtD
Midazolam—Paraesthesia—Methotrexate—muscle cancer	0.000242	0.002	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000242	0.002	CcSEcCtD
Midazolam—Dyspnoea—Methotrexate—muscle cancer	0.00024	0.00199	CcSEcCtD
Midazolam—Somnolence—Methotrexate—muscle cancer	0.00024	0.00198	CcSEcCtD
Midazolam—Dry mouth—Doxorubicin—muscle cancer	0.000238	0.00197	CcSEcCtD
Midazolam—Dyspepsia—Methotrexate—muscle cancer	0.000237	0.00197	CcSEcCtD
Midazolam—Confusional state—Doxorubicin—muscle cancer	0.000235	0.00195	CcSEcCtD
Midazolam—Anaphylactic shock—Doxorubicin—muscle cancer	0.000233	0.00193	CcSEcCtD
Midazolam—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000233	0.00193	CcSEcCtD
Midazolam—Fatigue—Methotrexate—muscle cancer	0.000232	0.00192	CcSEcCtD
Midazolam—Pain—Methotrexate—muscle cancer	0.00023	0.00191	CcSEcCtD
Midazolam—Shock—Doxorubicin—muscle cancer	0.00023	0.0019	CcSEcCtD
Midazolam—Nervous system disorder—Doxorubicin—muscle cancer	0.000229	0.0019	CcSEcCtD
Midazolam—Tachycardia—Doxorubicin—muscle cancer	0.000228	0.00189	CcSEcCtD
Midazolam—Skin disorder—Doxorubicin—muscle cancer	0.000227	0.00188	CcSEcCtD
Midazolam—Feeling abnormal—Methotrexate—muscle cancer	0.000222	0.00184	CcSEcCtD
Midazolam—Hypotension—Doxorubicin—muscle cancer	0.000218	0.00181	CcSEcCtD
Midazolam—Urticaria—Methotrexate—muscle cancer	0.000214	0.00177	CcSEcCtD
Midazolam—Paraesthesia—Doxorubicin—muscle cancer	0.00021	0.00174	CcSEcCtD
Midazolam—Dyspnoea—Doxorubicin—muscle cancer	0.000208	0.00172	CcSEcCtD
Midazolam—Somnolence—Doxorubicin—muscle cancer	0.000207	0.00172	CcSEcCtD
Midazolam—Dyspepsia—Doxorubicin—muscle cancer	0.000205	0.0017	CcSEcCtD
Midazolam—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000201	0.00167	CcSEcCtD
Midazolam—Fatigue—Doxorubicin—muscle cancer	0.000201	0.00167	CcSEcCtD
Midazolam—Pain—Doxorubicin—muscle cancer	0.0002	0.00165	CcSEcCtD
Midazolam—Constipation—Doxorubicin—muscle cancer	0.0002	0.00165	CcSEcCtD
Midazolam—Hypersensitivity—Methotrexate—muscle cancer	0.000199	0.00164	CcSEcCtD
Midazolam—Asthenia—Methotrexate—muscle cancer	0.000193	0.0016	CcSEcCtD
Midazolam—Feeling abnormal—Doxorubicin—muscle cancer	0.000192	0.00159	CcSEcCtD
Midazolam—Pruritus—Methotrexate—muscle cancer	0.000191	0.00158	CcSEcCtD
Midazolam—Urticaria—Doxorubicin—muscle cancer	0.000185	0.00154	CcSEcCtD
Midazolam—Dizziness—Methotrexate—muscle cancer	0.000178	0.00148	CcSEcCtD
Midazolam—Hypersensitivity—Doxorubicin—muscle cancer	0.000172	0.00142	CcSEcCtD
Midazolam—Vomiting—Methotrexate—muscle cancer	0.000171	0.00142	CcSEcCtD
Midazolam—Rash—Methotrexate—muscle cancer	0.00017	0.00141	CcSEcCtD
Midazolam—Dermatitis—Methotrexate—muscle cancer	0.00017	0.00141	CcSEcCtD
Midazolam—Headache—Methotrexate—muscle cancer	0.000169	0.0014	CcSEcCtD
Midazolam—Asthenia—Doxorubicin—muscle cancer	0.000167	0.00139	CcSEcCtD
Midazolam—Pruritus—Doxorubicin—muscle cancer	0.000165	0.00137	CcSEcCtD
Midazolam—Nausea—Methotrexate—muscle cancer	0.00016	0.00133	CcSEcCtD
Midazolam—Dizziness—Doxorubicin—muscle cancer	0.000154	0.00128	CcSEcCtD
Midazolam—Vomiting—Doxorubicin—muscle cancer	0.000148	0.00123	CcSEcCtD
Midazolam—Rash—Doxorubicin—muscle cancer	0.000147	0.00122	CcSEcCtD
Midazolam—Dermatitis—Doxorubicin—muscle cancer	0.000147	0.00122	CcSEcCtD
Midazolam—Headache—Doxorubicin—muscle cancer	0.000146	0.00121	CcSEcCtD
Midazolam—Nausea—Doxorubicin—muscle cancer	0.000139	0.00115	CcSEcCtD
